课题基金 / 基金详情

miRNA-9 delivery using lactosome, a newly-developed drug delivery system, in the treatment of rheumatoid arthritis

miRNA-9 delivery using lactosome, a newly-developed drug delivery system, in the treatment of rheumatoid arthritis
使用乳糖体(一种新开发的药物递送系统)递送 miRNA-9 来治疗类风湿性关节炎
批准号:
22K16341
负责人:
LEE WENSHI
金额:
$2.66万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Early-Career Scientists
财政年份:
2022
资助国家:
日本
项目状态:
已结题
起止时间:
2022-04-01 至 2024-03-31

项目摘要

项目成果

LEE WENSHI的其他基金

相似基金

相关文献

中文摘要
翻译
在胶原诱导的关节炎小鼠模型中静脉注射lactosome-mir 9,并以lactosome-control siRNA作为对照组,miR-9组的平均关节炎评分相对低于对照组。关节的组织学评估目前正在进行中。
英文摘要
We injected lactosome-mir9 intravenously into collagen-induced arthritis mouse model, with lactosome-control siRNA as control group.The mean arthritic score was relatively lower in miR-9 group compared to the control group. The histological assessments for the joints are currently under progress.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
  • 批准号:
    24K19237
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
  • 资助金额:
    $3.0万
  • 财政年份:
    2024
  • 负责人:
    LEE WENSHI
  • 依托单位:
国内基金
海外基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data